(Q36901955)

17 August 2017

1 reference

title

Potential biological targets of Bacillus anthracis in anti-infective approaches against the threat of bioterrorism (English)

1 reference

17 August 2017

0 references

Bacillus anthracis

1 reference

based on heuristic

inferred from title

author name string

Dimitrios G Bouzianas

series ordinal

1

1 reference

17 August 2017

publication date

1 August 2007

1 reference

Expert Review of Anti-infective Therapy

17 August 2017

published in

1 reference

17 August 2017

volume

5

1 reference

17 August 2017

issue

4

1 reference

17 August 2017

page(s)

665-684

1 reference

Anthrax as a biological weapon, 2002: updated recommendations for management

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax inhalation and lethal human infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Molecular basis for improved anthrax vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Bacillus anthracis virulence in Guinea pigs vaccinated with anthrax vaccine adsorbed is linked to plasmid quantities and clonality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

DNA sequence conservation between the Bacillus anthracis pXO2 plasmid and genomic sequence from closely related bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Bacillus anthracis pXO1 plasmid sequence conservation among closely related bacterial species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

CapE, a 47-amino-acid peptide, is necessary for Bacillus anthracis polyglutamate capsule synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Regulatory networks for virulence and persistence of Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Global Effects of Virulence Gene Regulators in a Bacillus anthracis Strain with Both Virulence Plasmids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Crystal structure of a complex between anthrax toxin and its host cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, "Bacillus-ACT05".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The alveolar macrophage: the Trojan horse of Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Pathophysiological manifestations in mice exposed to anthrax lethal toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Importance of nitric oxide synthase in the control of infection by Bacillus anthracis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax lethal toxin induces endothelial barrier dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax edema toxin sensitizes DBA/2J mice to lethal toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Past, imminent and future human medical countermeasures for anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

A phase 1 study of PAmAb, a fully human monoclonal antibody against Bacillus anthracis protective antigen, in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

A silent bomb: the risk of anthrax as a weapon of mass destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Efficient synthetic inhibitors of anthrax lethal factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Murine model of pulmonary anthrax: kinetics of dissemination, histopathology, and mouse strain susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Sepsis and pathophysiology of anthrax in a nonhuman primate model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Histopathology in a murine model of anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Additional conjugation methods and immunogenicity of Bacillus anthracis poly-gamma-D-glutamic acid-protein conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Poly-gamma-glutamate in bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The capsule of Bacillus anthracis behaves as a thymus-independent type 2 antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

mAbs to Bacillus anthracis capsular antigen for immunoprotection in anthrax and detection of antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

A dually active anthrax vaccine that confers protection against both bacilli and toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Induction of opsonic antibodies to the gamma-D-glutamic acid capsule of Bacillus anthracis by immunization with a synthetic peptide-carrier protein conjugate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Protective and immunochemical activities of monoclonal antibodies reactive with the Bacillus anthracis polypeptide capsule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax capsule vaccine protects against experimental infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Purified Bacillus anthracis lethal toxin complex formed in vitro and during infection exhibits functional and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Analysis of adverse events after anthrax immunization in US Army medical personnel

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Neutralizing antibodies and persistence of immunity following anthrax vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Scalable purification of Bacillus anthracis protective antigen from Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax vaccine powder formulations for nasal mucosal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Rabies virus glycoprotein as a carrier for anthrax protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Multicomponent anthrax toxin display and delivery using bacteriophage T4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large full-length proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Human-derived, plant-produced monoclonal antibody for the treatment of anthrax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Engineered chloroplasts as vaccine factories to combat bioterrorism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Induction of protective immunity against lethal anthrax challenge with a patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

DNA vaccines against anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Adenovirus-based prime-boost immunization for rapid vaccination against anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Point mutations in anthrax protective antigen that block translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Identification of the cellular receptor for anthrax toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Expression and purification of functional human anthrax toxin receptor (ATR/TEM8) binding domain from Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Polyvalent inhibitors of anthrax toxin that target host receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

LRP6 holds the key to the entry of anthrax toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax delivers a lethal blow to host immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The 2beta2-2beta3 loop of anthrax protective antigen contains a dominant neutralizing epitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Beta-cyclodextrin derivatives that inhibit anthrax lethal toxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Inhibition of anthrax protective antigen outside and inside the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Inhibition of furin by polyarginine-containing peptides: nanomolar inhibition by nona-D-arginine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Inter-alpha-inhibitor proteins are endogenous furin inhibitors and provide protection against experimental anthrax intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Stable peptide inhibitors prevent binding of lethal and oedema factors to protective antigen and neutralize anthrax toxin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Passive antibody administration (immediate immunity) as a specific defense against biological weapons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Human antibodies from immunized donors are protective against anthrax toxin in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Development of high-throughput assay of lethal factor using native substrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Cisplatin inhibition of anthrax lethal toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Metalloproteinase inhibitors, nonantimicrobial chemically modified tetracyclines, and ilomastat block Bacillus anthracis lethal factor activity in viable cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Cross-inhibition between furin and lethal factor inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Chemical screening by mass spectrometry to identify inhibitors of anthrax lethal factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Human alpha-defensins neutralize anthrax lethal toxin and protect against its fatal consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Retrocyclins kill bacilli and germinating spores of Bacillus anthracis and inactivate anthrax lethal toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax lethal factor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Cationic polyamines inhibit anthrax lethal factor protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Peptide inhibitors MAP the way towards fighting anthrax pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Potent inhibitors of anthrax lethal factor from green tea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Chloroquine enhances survival in Bacillus anthracis intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Production of biologically active Bacillus anthracis edema factor in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

N-fragment of edema factor as a candidate antigen for immunization against anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Bacillus anthracis edema toxin acts as an adjuvant for mucosal immune responses to nasally administered vaccine antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Search for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Characterization of anthrolysin O, the Bacillus anthracis cholesterol-dependent cytolysin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The Bacillus anthracis cholesterol-dependent cytolysin, Anthrolysin O, kills human neutrophils, monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The extracellular and cytoplasmic proteomes of the non-virulent Bacillus anthracis strain UM23C1-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Comparative secretome analyses of three Bacillus anthracis strains with variant plasmid contents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Surface protein IsdC and Sortase B are required for heme-iron scavenging of Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Structures of sortase B from Staphylococcus aureus and Bacillus anthracis reveal catalytic amino acid triad in the active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Structure of purine nucleoside phosphorylase (DeoD) from Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

A novel FtsZ-like protein is involved in replication of the anthrax toxin-encoding pXO1 plasmid in Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Characterization of Bacillus anthracis germinant receptors in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Formation and composition of the Bacillus anthracis endospore

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Novel oligosaccharide side chains of the collagen-like region of BclA, the major glycoprotein of the Bacillus anthracis exosporium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Identification of the immunodominant protein and other proteins of the Bacillus anthracis exosporium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The ExsY protein is required for complete formation of the exosporium of Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Identification of proteins in the exosporium of Bacillus anthracis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

DNA vaccination against anthrax in mice-combination of anti-spore and anti-toxin components

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Synthesis and antigenic analysis of the BclA glycoprotein oligosaccharide from the Bacillus anthracis exosporium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Contribution of ExsFA and ExsFB proteins to the localization of BclA on the spore surface and to the stability of the bacillus anthracis exosporium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Morphogenesis of bacillus spore surfaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Characterization of a major Bacillus anthracis spore coat protein and its role in spore inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Proteomics study of anthrax lethal toxin-treated murine macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Inhibition of mitogen-activated protein kinase signalling by Bacillus anthracis lethal toxin causes destabilization of interleukin-8 mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Novel repression of the glucocorticoid receptor by anthrax lethal toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax lethal toxin represses glucocorticoid receptor (GR) transactivation by inhibiting GR-DNA binding in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax mounts a nuclear attack on glucocorticoid signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax lethal factor represses glucocorticoid and progesterone receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Mitochondrial impairment is a critical event in anthrax lethal toxin-induced cytolysis of murine macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax pathogen evades the mammalian immune system through stealth siderophore production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Host-pathogen interactions: a proteomic view

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Bacillus anthracis and antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax toxins and the host: a story of intimacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Selection of Bacillus anthracis isolates resistant to antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

PlyPH, a bacteriolytic enzyme with a broad pH range of activity and lytic action against Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

A bacteriolytic agent that detects and kills Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The 1.6 A crystal structure of the catalytic domain of PlyB, a bacteriophage lysin active against Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Functional cloning of Bacillus anthracis dihydrofolate reductase and confirmation of natural resistance to trimethoprim

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Bacterial protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Protease inhibitors in the clinic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Anthrax toxins: A paradigm of bacterial immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The roles of anthrax toxin in pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Dominant-Negative Mutants of a Toxin Subunit: An Approach to Therapy of Anthrax

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Structural Determinants for the Binding of Anthrax Lethal Factor to Oligomeric Protective Antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

Immunization against anthrax using Bacillus subtilis spores expressing the anthrax protective antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

The effectiveness and safety of vaccines against human anthrax: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.5.4.665

21 January 2018

Identifiers

DOI

10.1586/14787210.5.4.665

1 reference

17 August 2017

1 reference